Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2013. The report details a specific share repurchase transaction executed on June 14, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 447,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,685.5 pence per share; lowest price paid was 1,668.0 pence per share.
- Treasury Holdings (Settled): 509,817,512 shares (9.39% of total issued share capital).
- Treasury Holdings (Including Unsettled): 511,188,512 shares (10.39% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,919,900,180 shares.
Material Changes
The filing reports an increase in the Company's treasury share holdings following the purchase of 447,000 shares. Consequently, the percentage of total voting rights held in treasury increased to 10.39% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, or contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (509,817,512 settled) against the latest quarterly reports.
- Confirm the total issued share capital to validate the 9.39% treasury ownership calculation.
- Check the settlement status of the 447,000 shares purchased on June 14, 2013, to reconcile the difference between settled and total treasury holdings.
- Review the remaining authorization for share buybacks under the mandate granted on May 1, 2013.